ZyVersa Therapeutics plans Phase 2a trial of Cholesterol Efflux Mediator VAR 200 for diabetic kidney disease in H2 2024.
ZyVersa Therapeutics, a clinical-stage biopharma firm, expects its Phase 2a trial for Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease to begin in H2 2024, with the first patient enrolled soon. The company also targets obesity with related metabolic complications as the lead indication for its Inflammasome ASC Inhibitor IC 100, with an IND submission planned in Q4 2024 followed by a Phase 1 trial in Q1 2025. Despite a Q2 net loss of $2.8M, ZyVersa made progress in R&D efforts, and its $0.1M cash reserves are expected to fund operations.
August 09, 2024
4 Articles